|Day Low/High||0.40 / 0.60|
|52 Wk Low/High||0.68 / 4.26|
Neostem (NBS) shares are falling after the company priced is secondary offering below its previous closing price.
Dr. Merrick Ross to Lead NeoStem's Phase 3 Trial of Immuno-Oncology Product Candidate NBS20
Company on Leading Edge of Research With Experimental Therapy Targeting Specific Cancer Cells
The most recent short interest data has been released by the NASDAQ for the 04/15/2015 settlement date, which shows a 388,121 share increase in total short interest for NeoStem Inc , to 3,125,226, an increase of 14.18% since 03/31/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The Intus Trial is Being Conducted Under a Special Protocol Assessment (SPA) With a Primary Endpoint of Overall Survival
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Amendment Adds Dedicated NeoStem Facilities and Personnel
Results Support Previous Observation of Dose-Dependent Signals Across Multiple Endpoints
The most recent short interest data was recently released by the NASDAQ for the 01/30/2015 settlement date, and NeoStem Inc is one of the most shorted stocks of the Russell 3000, based on 15.64 "days to cover" versus the median component at 5.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
License Allows Manufacture and Distribution of Eltrapuldencel-T (NBS20) for Clinical Trial Use
New System Will Support Commercial-Scale Manufacturing of Cell Therapies and Other Patient-Specific Products
Stocks with insider trader activity include UGI, NBS and MACK